These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26263903)

  • 1. Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.
    Park T; Griggs SK; Suh DC
    BioDrugs; 2015 Aug; 29(4):259-74. PubMed ID: 26263903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
    Schuller Y; Hollak CE; Biegstraaten M
    Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.
    Grand TS; Ren S; Hall J; Åström DO; Regnier S; Thokala P
    Pharmacoeconomics; 2024 Jun; 42(6):619-631. PubMed ID: 38616217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 8. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
    Picavet E; Cassiman D; Simoens S
    J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of available evidence on 11 high-priced inpatient orphan drugs.
    Kanters TA; de Sonneville-Koedoot C; Redekop WK; Hakkaart L
    Orphanet J Rare Dis; 2013 Aug; 8():124. PubMed ID: 23947946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.
    Dabbous O; Chachoua L; Aballéa S; Sivignon M; Persson U; Petrou S; Richardson J; Simoens S; Toumi M
    Adv Ther; 2023 Feb; 40(2):393-424. PubMed ID: 36451072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limits on use of health economic assessments for rare diseases.
    Hyry HI; Stern AD; Cox TM; Roos JC
    QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drugs: expensive yet necessary.
    Hyry HI; Roos JC; Cox TM
    QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.